$38.27
5.28% day before yesterday
NYSE, Aug 22, 10:00 pm CET
ISIN
US03770N1019
Symbol
APGE

Apogee Therapeutics Stock price

$38.27
-1.33 3.36% 1M
+4.90 14.68% 6M
-7.03 15.52% YTD
-9.55 19.97% 1Y
+17.04 80.26% 3Y
+17.04 80.26% 5Y
+17.04 80.26% 10Y
+17.04 80.26% 20Y
NYSE, Closing price Fri, Aug 22 2025
+1.92 5.28%
ISIN
US03770N1019
Symbol
APGE
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$1.8b
Net debt
positive
Cash
$505.4m
Shares outstanding
58.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.7
Financial Health
Equity Ratio
95.1%
Return on Equity
-25.4%
ROCE
-43.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-270.1m | $-288.4m
EBIT
$-270.8m | $-292.4m
Net Income
$-237.7m | $-260.3m
Free Cash Flow
$-226.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-88.0% | -33.1%
EBIT
-88.4% | -34.8%
Net Income
-100.6% | -42.9%
Free Cash Flow
-103.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.1
FCF per Share
$-3.9
Short interest
30.7%
Employees
196
Rev per Employee
$0.0
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Apogee Therapeutics forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Apogee Therapeutics forecast:

Buy
93%
Hold
7%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 63 63
75% 75%
-
- Research and Development Expense 208 208
93% 93%
-
-270 -270
88% 88%
-
- Depreciation and Amortization 0.73 0.73
943% 943%
-
EBIT (Operating Income) EBIT -271 -271
88% 88%
-
Net Profit -238 -238
101% 101%
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Neutral
GlobeNewsWire
13 days ago
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis
Positive
Seeking Alpha
about 2 months ago
Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact, APG777 could potentially disrupt the massive AT market, which is currently dominated by Dupixent. APGE's Phase 2 trial, called APEX Part A, exceeded its targets. We also have to wait until 1H2026...
Positive
Proactive Investors
about 2 months ago
Apogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial met its primary endpoint with a 71% reduction in Eczema Area Severity Index (EASI) score at Week 16, versus 33.8% for placebo.
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Employees 196
Founded 2022
Website apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today